Bodhi Tree Biotechnology Inc. (BDTB) intrinsic value & 10-year financials
Bodhi Tree Biotechnology Inc. (BDTB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 2 fiscal years revenue reached to $17.0K, with an average return on invested capital of -76.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.28
- Market cap
- $7.2M
- Revenue (FY2025)
- $17.0K
- ROIC (10-yr avg)
- -76.1%
- Free cash flow (FY2025)
- —
BDTB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $17.0K | -$149.7K | -$0.01 | — | -868.3% | -76.1% |
| FY2024 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bodhi Tree Biotechnology Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bodhi Tree Biotechnology Inc has historically struggled to out-earn its cost of capital, averaging just -76.1% ROIC.
Bodhi Tree Biotechnology Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Bodhi Tree Biotechnology Inc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.